Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 4Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 233Neoplasms 201Carcinoma, Non-Small-Cell Lung 99Colorectal Neoplasms 97Prostatic Neoplasms 94Lung Neoplasms 77Multiple Myeloma 54Melanoma 52Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Carcinoma, Hepatocellular 45Leukemia, Myeloid, Acute 42Brain Neoplasms 40Ovarian Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Uterine Cervical Neoplasms 32Glioblastoma 31Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma 27Glioma 27Stomach Neoplasms 26Lymphoma, Non-Hodgkin 26Colonic Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Rectal Neoplasms 24Lymphoma, Large B-Cell, Diffuse 23

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Nerve Tissue × 90 days × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡